All In Biotech

Drug Trial Radar · NCT04349410

The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol

Last checked: Nov 19, 2026Latest source record: Nov 12, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,800 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,800

Actual

Start

Apr 11, 2020

Primary completion

Sep 14, 2020

Study completion Sep 14, 2020

Sponsor

Lead sponsor
The Camelot FoundationAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 16, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Factorial
Masking
Single (investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Diagnostic determination of disease and treatment responses has been limited to qualitative imaging, measurement of serum markers of disease, and sampling of tissue. In each of these instances, there is a built in error either due to sensitivity and specificity issues, clinician interpretation of results, or acceptance of the use of an indirect marker (blood test) of what is happening elsewhere in the body - at the tissue level. The Fleming Method for Tissue and Vascular Differentiation and Metabolism (FMTVDM) using same state single or sequential quantification comparisons \[1\] provides the first and only patented test (#9566037) - along with the associated submitted patent applications ruled to be covered under #9566037 - that quantitatively measures changes in tissue resulting from inter alia a disease process. This includes inter alia coronary artery disease (CAD), cancer and infectious/inflammatory processes including CoVid-19 pneumonia (CVP) resulting from the metabolic and regional blood flow differences (RBFDs) caused by these diseases. The purpose of this paper is to make clinicians and researchers aware of this proposed method for investigating the prevalence and severity of CVP - in addition to providing rapid determination of treatment response in each patient, directing treatment decisions; thereby reducing the loss of time, money, resources and patient lives.

Conditions

  • CoVid 19 Positive

Interventions

  • Hydroxychloroquine, AzithromycinDrug

    FMTVDM Planar, SPECT, PET

  • Hydroxychloroquine, DoxycyclineDrug

    FMTVDM Planar, SPECT, PET

  • Hydroxychloroquine, ClindamycinDrug

    FMTVDM Planar, SPECT, PET

  • Hydroxychloroquine, Clindamycin, Primaquine - low dose.Drug

    FMTVDM Planar, SPECT, PET

  • Hydroxychloroquine, Clindamycin, Primaquine - high dose.Drug

    FMTVDM Planar, SPECT, PET

  • RemdesivirDrug

    FMTVDM Planar, SPECT, PET

  • TocilizumabDrug

    FMTVDM Planar, SPECT, PET

  • MethylprednisoloneDrug

    FMTVDM Planar, SPECT, PET

  • Interferon-Alpha2BDrug

    FMTVDM Planar, SPECT, PET

  • LosartanDrug

    FMTVDM Planar, SPECT, PET

  • Convalescent SerumDrug

    FMTVDM Planar, SPECT, PET

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Improvement in FMTVDM Measurement with nuclear imaging.Time frame: 72 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • FHHI-OI-Camelot; QME

    Los Angeles, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.